Compare · CNSP vs NVO
CNSP vs NVO
Side-by-side comparison of CNS Pharmaceuticals Inc. (CNSP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNSP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 28371.5x CNSP ($6.7M).
- Over the past year, CNSP is down 60.0% and NVO is down 44.1% - NVO leads by 15.9 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 7 for CNSP).
- NVO has more recent analyst coverage (25 ratings vs 0 for CNSP).
- Company
- CNS Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $4.44-3.69%
- $43.97+2.76%
- Market cap
- $6.7M
- $191.15B
- 1M return
- -30.73%
- -6.43%
- 1Y return
- -60.04%
- -44.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 7
- 8
- Recent ratings
- 0
- 25
CNS Pharmaceuticals Inc.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CNSP
- CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment
- SEC Form EFFECT filed by CNS Pharmaceuticals Inc.
- SEC Form 424B3 filed by CNS Pharmaceuticals Inc.
- Director Charles Faith L. bought $34,002 worth of shares (7,100 units at $4.79) (SEC Form 4)
- CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
- SEC Form D filed by CNS Pharmaceuticals Inc.
- SEC Form S-3 filed by CNS Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by CNS Pharmaceuticals Inc.
- CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
- SEC Form 10-Q filed by CNS Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care